290 related articles for article (PubMed ID: 32790899)
1. Novel insights into the function of CD24: A driving force in cancer.
Altevogt P; Sammar M; Hüser L; Kristiansen G
Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
[TBL] [Abstract][Full Text] [Related]
2. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
3. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
Chen C; Zhang L; Ruan Z
Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
6. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression.
Lin CY; Tsai CL; Chao A; Lee LY; Chen WC; Tang YH; Chao AS; Lai CH
J Mol Med (Berl); 2021 Aug; 99(8):1125-1137. PubMed ID: 33954835
[TBL] [Abstract][Full Text] [Related]
7. The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo.
Shapira S; Kazanov D; Weisblatt S; Starr A; Arber N; Kraus S
J Biol Chem; 2011 Nov; 286(47):40548-55. PubMed ID: 21976680
[TBL] [Abstract][Full Text] [Related]
8. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.
Chen GY; Tang J; Zheng P; Liu Y
Science; 2009 Mar; 323(5922):1722-5. PubMed ID: 19264983
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface.
Sammar M; Siwetz M; Meiri H; Fleming V; Altevogt P; Huppertz B
Histochem Cell Biol; 2017 May; 147(5):565-574. PubMed ID: 28012129
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint CD24 function on tumor and immunotherapy.
Huang S; Zhang X; Wei Y; Xiao Y
Front Immunol; 2024; 15():1367959. PubMed ID: 38487533
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis.
Kristiansen G; Machado E; Bretz N; Rupp C; Winzer KJ; König AK; Moldenhauer G; Marmé F; Costa J; Altevogt P
Lab Invest; 2010 Jul; 90(7):1102-16. PubMed ID: 20351695
[TBL] [Abstract][Full Text] [Related]
12. The biological roles of CD24 in ovarian cancer: old story, but new tales.
Gu Y; Zhou G; Tang X; Shen F; Ding J; Hua K
Front Immunol; 2023; 14():1183285. PubMed ID: 37359556
[TBL] [Abstract][Full Text] [Related]
13. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.
Wang X; Liu M; Zhang J; Brown NK; Zhang P; Zhang Y; Liu H; Du X; Wu W; Devenport M; Tao W; Mao-Draayer Y; Chen GY; Chen YE; Zheng P; Liu Y
Cell Metab; 2022 Aug; 34(8):1088-1103.e6. PubMed ID: 35921817
[TBL] [Abstract][Full Text] [Related]
14. Overview of CD24 as a new molecular marker in ovarian cancer.
Tarhriz V; Bandehpour M; Dastmalchi S; Ouladsahebmadarek E; Zarredar H; Eyvazi S
J Cell Physiol; 2019 Mar; 234(3):2134-2142. PubMed ID: 30317611
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10.
Yin SS; Gao FH
Front Immunol; 2020; 11():1324. PubMed ID: 32765491
[TBL] [Abstract][Full Text] [Related]
16. SIRT1-Mediated Expression of CD24 and Epigenetic Suppression of Novel Tumor Suppressor miR-1185-1 Increases Colorectal Cancer Stemness.
Wang TW; Chern E; Hsu CW; Tseng KC; Chao HM
Cancer Res; 2020 Dec; 80(23):5257-5269. PubMed ID: 33046442
[TBL] [Abstract][Full Text] [Related]
17. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer.
Smith SC; Oxford G; Wu Z; Nitz MD; Conaway M; Frierson HF; Hampton G; Theodorescu D
Cancer Res; 2006 Feb; 66(4):1917-22. PubMed ID: 16488989
[TBL] [Abstract][Full Text] [Related]
18. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer.
Mishra AK; Ye T; Banday S; Thakare RP; Su CT; Pham NNH; Ali A; Kulshreshtha A; Chowdhury SR; Simone TM; Hu K; Zhu LJ; Eisenhaber B; Deibler SK; Simin K; Thompson PR; Kelliher MA; Eisenhaber F; Malonia SK; Green MR
Cell Rep; 2024 Apr; 43(4):114041. PubMed ID: 38573857
[TBL] [Abstract][Full Text] [Related]
19. Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway.
Wang K; Yu A; Liu K; Feng C; Hou Y; Chen J; Ma S; Huang L; Dai X
Adv Sci (Weinh); 2023 May; 10(13):e2300288. PubMed ID: 36866919
[TBL] [Abstract][Full Text] [Related]
20. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
